To amend the Federal Food, Drug, and Cosmetic Act to establish a process for externally led, science-focused drug development meetings, and for other purposes.

The bill, designated as H.R. 9979 in the 118th Congress, aims to amend the Federal Food, Drug, and Cosmetic Act to create a framework for externally led, science-focused drug development meetings. The bill likely proposes establishing a structured process for such meetings to enhance collaboration and scientific input in drug development activities.